Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 07/01/2009 - (DGNews)
    Certain Clinical, Ultrasonographic Characteristics Can Assist in Diagnosing Uveal Melanoma: Presented at COS - (DGDispatch)
    TopAbstracts in Melanoma 06/03/2009 - (DGNews)
    Ipilimumab Benefits Patients With Advanced Melanoma Regardless of Immune-Related Adverse Events: Presented at ASCO - (DGDispatch)
    Actinic Keratoses Responsible for More Cancer Types Than Once Believed - (DGNews)

    News archive

     Recent webcasts/CME - Melanoma

    Webcasts/CME archive

     Recent cases - Melanoma
      Nasal Mucosal Melanoma Presenting as Central Type Vertigo
      Malignant Melanoma Associated with a Blue Naevus: A Case Report
      Metastatic Malignant Melanoma of the Conjunctiva and a Report of Long Bone Involvement: A Case Report
      Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer
      A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek

      Cases archive
        




      my personal edition > melanoma > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Sentinel Node Number Predicts 5-Year Melanoma Survival in Database Analysis: Presented at SSO

      By Carole Bullock

      CHICAGO -- March 20, 2008 -- The risk of metastatic melanoma risk is higher for patients with 1 or more positive sentinel lymph nodes (SLNs) compared with patients who have negative SNLs, according to a large database analysis presented here at the Society of Surgical Oncology (SSO) 61st Annual Cancer Symposium.

      "The 5-year survival of patients with positive sentinel nodes was 70.6% in those with only 1 positive node and 55.6% when 2 or more nodes were positive," said investigator Alessandro Testori, MD, Director, Melanoma and Soft Tissue Sarcoma Division, European Institute of Oncology, Milan, Italy.

      The observational multicentre study examined SNL biopsies and reported the false negative (FN) rate, possible correlations between prognostic factors and SLN status, and prognosis after biopsy.

      The study was conducted in 23 centres in Italy and included 1,313 consecutive patients enrolled from January 2000 to December 2002 with primary cutaneous melanoma located in the lower limbs or upper limbs, head, neck, or trunk.

      Lymphoscintigraphy, blue dye lymphatic mapping, pathological examination, and follow-up were performed according to the study protocol.

      The SLN identification rate was 99.3%. Mean number of SLNs was 2.0 (range 1–17) and only 1 node was removed in 45.4 %, Dr. Testori reported in a poster session on March 14.

      Multivariate Cox regression analysis indicated that SLN status was the most important prognostic factor (hazard ratio = 3.08), followed by gender and age, as well as Breslow and Clark level (which indicates the invasiveness of the tumour).

      Ulceration, which was associated with survival when considered as a single factor (P < .0001) had no impact on survival in the multivariate analysis.

      The positivity and false-negative rates were 16.9% and 18.4%, respectively (median follow-up, 4.5 years).

      Multivariate logistic regression analysis showed that the frequency of positive nodes increased with increasing Breslow's thickness (P < .0001) and Clark level (P = .047).

      Positive SLN status was associated with female sex (P = .007) and melanoma regression (P = .0002). Presence of macrometastasis was associated with an increasing number of positive SLNs (P = .009).

      The false-negative rate of SLN biopsy was approximately 20%.

      "Regression in the primary melanoma seems to be a protective factor from metastasis in [SLNs]," Dr. Testori reported. "Macrometastases seem to influence the number of positive nodes."

      SLN biopsy makes it possible to assess the patient's prognosis, he explained. The researchers identified 3 groups of patients with different prognoses, he said. After 7 years, survival was about 90% among patients with negative SLN who did not develop metastases during follow-up, whereas patients with only 1 positive SLN and completion node dissection had a rate of about 44% survival. Patients with more than 1 positive SN after SLN biopsy and completion lymph node dissection-positive patients with false-negative SLN had a survival rate of about 40%, Dr. Testori said.


      [Presentation title: Clinical Outcome After Sentinel Node Biopsy in 1,313 Patients With Cutaneous Melanoma: An Italian Multicentric Study (SOLISM–IMI). Abstract P101]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send